Fig 1.
The mean of clinical activity score (CAS) in different groups with Graves’ ophthalmopathy.
The mean CAS score was significantly higher in males than in females (P = 0.008). The mean CAS score in smokers with GO was higher than that in non-smokers, with no statistically significant differences (P = 0.872).
Table 1.
Demographic and clinical data of GO patients.
Fig 2.
a, b. TSI and TSHR-ab levels in each group. Abbreviation: GO, Graves’ ophthalmopathy; GD, Graves’ disease.
Fig 3.
ROC curve analysis comparing TSHR-ab between GO and GD vs. controls.
Cutoff value >106.04 pg/mL. Area under the ROC curve (AUC) = 0.908. (95% CI, 0.864–0.942), p<0.0001. Positive percentage agreement (PPA) or. Sensitivity = 80.98% (95% CI, 74.1–86.7). Negative percentage agreement (NPA) or Specificity = 96.0 (95% CI, 88.8–99.2). Youden Index J = 0.7698.
Fig 4.
ROC curve analysis comparing TSI between GO vs. GD and controls.
Cutoff value >14.1 IU/mL Area under the ROC curve (AUC) = 0.933. (95% CI, 0.893–0.961), p<0.0001. Positive percentage agreement (PPA) or Sensitivity = 98.78% (95% CI, 93.4–100.0). Negative percentage agreement (NPA) or Specificity = 83.97% (95% CI, 77.3–89.4). Youden Index J = 0.8275.
Table 2.
The TSI and TSHR-ab levels in GD and GO.